Yaniv I, Stein J
Department of Pediatric Hematology Oncology and BMT Unit, Schneider Children's Medical Center of Israel, Petah-Tikva, Israel.
Bone Marrow Transplant. 2008 Jun;41 Suppl 2:S18-22. doi: 10.1038/bmt.2008.48.
Transplant-related mortality and morbidity (both short and long term) have limited the effectiveness of SCT in children with both malignant and nonmalignant diseases. Reduced-intensity preparative regimens permit engraftment of allogeneic cells without many of the toxicities associated with standard TBI- and non-TBI-based conditioning. We review the concepts that underlie reduced-intensity transplantation (RIT) and highlight the experience of the technique in children. Although acute organ damage may be reduced after these transplants, the overall incidence of severe infections and of GvHD may be similar to that seen after standard-intensity transplantation. The relatively small numbers of children who have received RIT and the newness of the technique preclude long-term follow-up with which to monitor the incidence of associated long-term side effects and disease-free survival. Future refinements in RIT and appropriate patient selection for these procedures will hopefully extend its utility in the future.
与移植相关的死亡率和发病率(包括短期和长期)限制了异基因造血干细胞移植(SCT)在患有恶性和非恶性疾病儿童中的有效性。降低强度的预处理方案可使异基因细胞植入,而没有许多与基于标准全身照射(TBI)和非TBI的预处理相关的毒性。我们回顾了降低强度移植(RIT)的基本概念,并强调了该技术在儿童中的应用经验。尽管这些移植后急性器官损伤可能会减少,但严重感染和移植物抗宿主病(GvHD)的总体发生率可能与标准强度移植后相似。接受RIT的儿童数量相对较少,且该技术尚新,因此无法进行长期随访以监测相关长期副作用的发生率和无病生存率。未来RIT的改进以及这些程序的合适患者选择有望在未来扩大其应用范围。